David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6...
-
Upload
isabel-preston -
Category
Documents
-
view
218 -
download
0
Transcript of David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6...
![Page 1: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/1.jpg)
STRATEGY FOR COMBATTING THE
RISE OF DRUG-RESISTANT
BACTERIA IN THE US
David Marash-Whitman11/20/13
![Page 2: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/2.jpg)
![Page 3: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/3.jpg)
KPC(Klebsiella
pneumoniaecarbapenemase)
18 infected patients
6 fatalities
complete drug resistance
persistent presence at
NIH center
![Page 4: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/4.jpg)
THE PROBLEM
increased usage leadsto decreased future effectiveness
antibiotics are being used excessively
development of new antibioticsis expensive
finite source of future antibiotics
![Page 5: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/5.jpg)
THE SOLUTION
promote conservative use of antibiotics
incentive to comply
remove barriers to compliance
![Page 6: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/6.jpg)
THE SOLUTION
bioethical responsibility
timeliness affordability
![Page 7: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/7.jpg)
THE SOLUTION
bioethical responsibility
timeliness affordability
![Page 8: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/8.jpg)
THE SOLUTION
bioethical responsibility
timeliness affordability
![Page 9: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/9.jpg)
THE SOLUTION
promote conservative use of antibiotics
increase incentive to comply
remove barriers to compliance
![Page 10: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/10.jpg)
THE SOLUTION
Prove-It SepsisSeptifast Sepsitest
$50
6 hours
25 species
$75
3.5 hours
70 species
$125
<1 hour
345 species
![Page 11: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/11.jpg)
THE SOLUTION
bioethical responsibility
timeliness affordability
![Page 12: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/12.jpg)
THE SOLUTION
bioethical responsibility
timeliness affordability
![Page 13: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/13.jpg)
OUTCOMES
accessibility of medical technology
reduction of inappropriateantibiotic prescriptions
![Page 14: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/14.jpg)
![Page 15: David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.](https://reader035.fdocuments.in/reader035/viewer/2022062314/56649ebc5503460f94bc4e74/html5/thumbnails/15.jpg)
SHORT TERMPREVENTION LONG TERM
general health
vaccination
development ofnew antibiotics
conservative useof antibiotics(in humans)(in animals)
development ofnew antimicrobial
therapies